Among genetic factors, variants of cytochrome P450 (CYP), primarily of CYP 2C19 and PON1 are important contributors to the variability in response to clopidogrel [3] [4][5][6]
The goal of this study was to investigate the associations of polymorphisms of CYP3A4, NR1I2, CYP2C19 and P2RY12 genes with CR in Chinese patients with ischemic stroke
61%, 15 CYP2C19 polymorphisms and clopidogrel 11287 to the genetic polymorphism in the CYP oxidative to determine the prevalence of genetic CYP2C19 polymorphisms in Iraqi patients and their effects Results: There was no significant association between polymorphism of the studied CYPs and clopidogrel responsiveness (P> 0
This observational retrospective study assessed the antiplatelet response and the prevalence of hemorrhagic or ischemic events after percutaneous neurointervention in clopidogrel-treated patients, related to 35 polymorphisms in the genes encoding the clopidogrel-metabolizing enzymes (CYP2C19, CYP1A2, CYP2B6, CYP2C9, CYP2C9, CYP3A4, CYP3A5, carboxylesterase-1 [CES1], and paraoxonase-1 CYP2C19 genotypes had significant impact on clopidogrel response and prognosis of patients with stroke, and regression analysis showed that CYP2C 19 was an independent predictor of clopIDogrel resistance
The frequency of the CYP2C9*3 allele was significantly lower among the Northern Thai population (P < 0
Importantly, the corresponding genes are highly polymorphic and Background Different platelet function tests can be used to evaluate the degree of achieved platelet inhibition in patients treated with clopidogrel
Gene polymorphism amongst different individuals would vary in changes at the level of functional proteins, which thus influence the degree of The influence of CYP 2C19* 2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement
Recently, our paper 10) reviewed a difference in the effect of the CYP2C19 PM genotype Similarly, the prevalence of HPR was associated with CYP2C19*2 and CYP2C19*3 (P < 0
The PBPK model was well validated for both clopidogrel and its Severe BSS and CYP2C19*2 gene mutation are associated with LCR, and could increase the risk of post-PCI cardiovascular events recurrence in patients with CAHD
However, investigating and validating trans -acting factors is much more difficult due to the more indirect nature of interaction which is more likely to be masked by covariates, thus necessitating The aim of this study was to evaluate the influence of CYP3A4*1G (IVS10+12G>A, rs2242480) on the pharmacokinetics and pharmacodynamics of clopidogrel
This review summarised the possible effects of genetic polymorphism on CR among the Asian population, especially CYP2C19 *2 / *3 / *17, where the prevalence rate among Asians was 23
35% of the Hakka population harboring the homozygous *3/*3 genotype; therefore, the wild-type allele CYP2C19*1 exhibited the highest Request PDF | Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention | Purpose: Clopidogrel is a Background
Prior knowledge of allele frequencies of cytochrome P450 polymorphisms in a population is crucial for the revision and optimization of existing medication choices and doses
00%, 4
Consequently, ethnic-related polymorphism in CYP3A4 and diet may be one underlying mechanism of response to medical regimes
Introduction
2021 Mar 9;21 (1):104
It is important for the treatment and prevention of coronary heart disease
Herein, this review focuses on the effect of genetic polymorphisms on clopidogrel response variability across the world stratified by patient ancestry, ethnicity
Clopidogrel is a widely-used antiplatelet drug
Prevalence and types of genetic polymorphisms of CYP2C19 and their effects on platelet aggregation inhibition by clopidogrel November 2020 European
Introduction: Clopidogrel is an antiplatelet prodrug primarily prescribed to prevent or treat acute coronary syndrome (ACS) or acute ischemic stroke (IS)
Results: There was no significant association between polymorphism of the studied CYPs and clopidogrel responsiveness (P> 0
Genetic variation in the cytochrome P450 2C19 (CYP2C19) gene has been documented gradually as the determinant conversion and variability in the antiplatelet effect of clopidogrel
This observational retrospective study assessed the antiplatelet response and the prevalence of hemorrhagic or ischemic events after percutaneous neurointervention in clopidogrel-treated patients, related to 35 polymorphisms in the genes encoding the clopidogrel-metabolizing enzymes (CYP2C19, CYP1A2, CYP2B6
Pharmacogenomics is the study of genetic variants that influence drug effects, typically through alterations in pharmacokinetics and pharmacodynamics 2
The presence of CYP 2C19*2 polymorphism can reduce the formation of the active metabolite of clopidogrel, resulting in less platelet inhibition
; There are still many unknowns
et al
Methods: Totally, 111 In the present study, a dynamic physiologically based pharmacokinetic (PBPK) model was developed in Simcyp for clopidogrel and clopi-H4 using a specific s
001 and P = 0
Conclusions: Given the varied effectiveness of clopidogrel due to its metabolism by CYP2C19 enzyme, and the relatively high frequency of both gain-of-function (18
However, investigating and validating trans -acting factors is much more difficult due to the more indirect nature of interaction which is more likely to be masked by covariates, thus